Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19271553 | GLP-1R Agonist and Therapeutic Method Thereof | July 2025 | December 2025 | Allow | 5 | 0 | 1 | No | No |
| 19250968 | SOLID STATE FORMS | June 2025 | August 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19250765 | SOLID STATE FORMS | June 2025 | August 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19249435 | MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER | June 2025 | August 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19230319 | DIPYRIDINE BENZOTHIOPHENE DERIVATIVE COMPOUND | June 2025 | July 2025 | Allow | 2 | 0 | 0 | No | No |
| 19224601 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | May 2025 | November 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19218087 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | May 2025 | August 2025 | Allow | 2 | 1 | 0 | Yes | No |
| 19094486 | AZAINDOLE ROCK INHIBITORS | March 2025 | May 2025 | Allow | 2 | 0 | 0 | No | No |
| 19089839 | INHIBITORS OF NLRP3 INFLAMMASOME | March 2025 | October 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19084086 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | March 2025 | October 2025 | Allow | 7 | 1 | 0 | No | No |
| 19072846 | COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF | March 2025 | July 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19002520 | COMPOUNDS FOR ACTIVATING A SEROTONIN RECEPTOR | December 2024 | May 2025 | Allow | 5 | 1 | 0 | No | No |
| 18987521 | PROCESS FOR PREPARING 7-CHLORO-6-FLUORO-1-(2-ISOPROPYL-4-METHYLPYRIDIN-3-YL)PYRIDO[2,3-D]PYRIMIDINE-2,4(1H,3H)-DIONE | December 2024 | June 2025 | Allow | 6 | 1 | 0 | No | No |
| 18988131 | PROCESS FOR PREPARING 4-METHYL-2-PROPAN-2-YL-PYRIDINE-3-CARBONITRILE | December 2024 | August 2025 | Allow | 8 | 1 | 0 | No | No |
| 18959040 | NOVEL PHENYLPYRAZOLE INSECTICIDE COMPOUNDS AND COMPOSITIONS | November 2024 | May 2025 | Allow | 6 | 1 | 0 | No | No |
| 18952401 | SOLID FREEBASE FORMS OF 5-CHLORO-2-(4-((2-HYDROXY-2-METHYLPROPYL)AMINO)PYRIDO[3,4-D]PYRIDAZIN-1-YL)PHENOL FOR INHIBITING NLRP3 AND USES THEREOF | November 2024 | October 2025 | Allow | 11 | 2 | 0 | No | No |
| 18935099 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | November 2024 | January 2025 | Allow | 2 | 0 | 0 | No | No |
| 18935253 | MODULATORS OF DCN-1 AND METHODS OF USE THEREOF | November 2024 | January 2025 | Allow | 2 | 0 | 0 | No | No |
| 18929263 | SELECTIVE LIGANDS FOR TAU AGGREGATES | October 2024 | January 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 18918161 | PTPN2/PTP1B Degrader and Therapeutic Method Thereof | October 2024 | December 2024 | Allow | 2 | 0 | 0 | No | No |
| 18914975 | AZAINDOLE ROCK INHIBITORS | October 2024 | January 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 18855229 | AN IMPROVED PROCESS FOR THE PREPARATION OF REMIMAZOLAM | October 2024 | October 2025 | Allow | 12 | 0 | 1 | Yes | No |
| 18808641 | COMPOUNDS FOR FGFR INHIBITION | August 2024 | February 2025 | Allow | 6 | 0 | 1 | No | No |
| 18785350 | PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | July 2024 | April 2025 | Allow | 9 | 2 | 0 | No | No |
| 18783394 | KRAS G12C INHIBITORS | July 2024 | October 2024 | Allow | 2 | 0 | 0 | No | No |
| 18763277 | PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | July 2024 | September 2024 | Allow | 2 | 1 | 0 | No | No |
| 18763243 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | July 2024 | December 2024 | Allow | 5 | 1 | 0 | No | No |
| 18763258 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | July 2024 | December 2024 | Allow | 5 | 1 | 0 | No | No |
| 18619017 | INTEGRIN INHIBITOR AND USES THEREOF | March 2024 | January 2026 | Allow | 22 | 0 | 0 | Yes | No |
| 18580664 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | January 2024 | March 2026 | Allow | 26 | 0 | 0 | Yes | No |
| 18416741 | SALTS AND CRYSTAL FORMS OF OMECAMTIV MECARBIL | January 2024 | December 2025 | Allow | 23 | 1 | 0 | No | No |
| 18545201 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | December 2023 | August 2025 | Allow | 20 | 1 | 0 | No | No |
| 18537371 | SOLID FORMS OF EMETINE | December 2023 | September 2025 | Allow | 22 | 1 | 0 | No | No |
| 18568744 | ISOINDOLINONE COMPOUNDS, AND USES THEREOF | December 2023 | March 2026 | Allow | 27 | 0 | 0 | Yes | No |
| 18531523 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | December 2023 | October 2025 | Allow | 22 | 1 | 1 | No | No |
| 18530017 | ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH | December 2023 | June 2025 | Allow | 18 | 1 | 0 | No | No |
| 18523171 | Antibacterial Compounds | November 2023 | August 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18518436 | NOVEL METHODS | November 2023 | May 2025 | Allow | 18 | 3 | 0 | No | Yes |
| 18516626 | PROCESS FOR MAKING A PD-1/PD-L1 INHIBITOR AND SALTS AND CRYSTALLINE FORMS THEREOF | November 2023 | April 2025 | Allow | 16 | 0 | 1 | No | No |
| 18386084 | AMPK ACTIVATORS | November 2023 | July 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18382927 | SOLID STATE FORMS | October 2023 | July 2025 | Allow | 20 | 2 | 0 | Yes | No |
| 18287610 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | October 2023 | July 2025 | Allow | 20 | 1 | 0 | No | No |
| 18554525 | BICYCLIC PYRIDINE DERIVATIVE | October 2023 | July 2025 | Allow | 22 | 1 | 1 | No | No |
| 18553923 | PROCESS FOR THE PREPARATION OF DROSPIRENONE AS A FINE POWDER THROUGH A DOUBLE CHANGE OF CRYSTALLINE FORM | October 2023 | January 2026 | Allow | 27 | 0 | 0 | No | No |
| 18480925 | PYRIDAZINE COMPOUNDS FOR INHIBITING NLRP3 | October 2023 | April 2025 | Allow | 18 | 1 | 0 | Yes | No |
| 18553829 | HYDROXYPYRIDINE HSD17B13 INHIBITORS AND USES THEREOF | October 2023 | January 2026 | Allow | 27 | 0 | 0 | No | No |
| 18480164 | PYRIDAZINE COMPOUNDS FOR INHIBITING NLRP3 | October 2023 | October 2024 | Allow | 13 | 0 | 0 | No | No |
| 18475499 | SMALL MOLECULAR INHIBITORS OF NF-kB INDUCING KINASE | September 2023 | August 2025 | Allow | 23 | 2 | 1 | Yes | No |
| 18371647 | INHIBITING CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) BINDING PROTEIN (CBP) | September 2023 | March 2025 | Allow | 18 | 2 | 0 | No | No |
| 18471017 | BENZAMIDE COMPOUNDS | September 2023 | September 2025 | Abandon | 24 | 1 | 1 | No | No |
| 18462229 | USE OF EZH2 INHIBITORS FOR TREATING CANCER | September 2023 | April 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18456301 | BRD9 DEGRADERS AND USES THEREOF | August 2023 | April 2025 | Abandon | 19 | 0 | 1 | No | No |
| 18232033 | POLYMORPHS OF THE HYDROCHLORIDE SALT OF LINAPRAZAN GLURATE | August 2023 | March 2025 | Allow | 20 | 2 | 0 | No | No |
| 18263432 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | July 2023 | March 2026 | Allow | 31 | 0 | 1 | Yes | No |
| 18263249 | SULFONYL BENZAMIDE DERIVATIVES AS BCL-2 INHIBITORS | July 2023 | November 2025 | Allow | 28 | 0 | 0 | Yes | No |
| 18273315 | CRYSTALLINE FORMS OF A PYRROLOPYRIDINE-ANILINE COMPOUND | July 2023 | February 2026 | Allow | 31 | 1 | 0 | No | No |
| 18273225 | PYRIDINE DERIVATIVES AS MODULATORS OF SORTILIN ACTIVITY | July 2023 | March 2026 | Allow | 31 | 0 | 1 | Yes | No |
| 18347491 | CRYSTALLINE FORMS OF AN S1P RECEPTOR MODULATOR | July 2023 | February 2026 | Allow | 32 | 1 | 0 | No | No |
| 18216392 | COMPOUNDS AND USES THEREOF | June 2023 | December 2024 | Allow | 17 | 3 | 0 | No | Yes |
| 18259029 | AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | June 2023 | September 2025 | Allow | 27 | 0 | 0 | No | No |
| 18212324 | FLUORINATED INTEGRIN ANTAGONISTS | June 2023 | August 2025 | Allow | 26 | 1 | 1 | No | No |
| 18268577 | 4-AMINO-3-(4-PHENOXYPHENYL)-1,3-DIHYDRO-2H-IMIDAZO[4,5-C]PYRIDIN-2-ONE DERIVATIVES AND SALTS THEREOF | June 2023 | October 2025 | Allow | 28 | 0 | 0 | No | No |
| 18258512 | TYK2 INHIBITORS AND USES THEREOF | June 2023 | February 2026 | Allow | 32 | 1 | 0 | No | No |
| 18257318 | PYRROLO[3,2-B]PYRIDINE DERIVATIVES USEFUL IN TREATING CONDITIONS ASSOCIATED WITH CGAS | June 2023 | September 2025 | Allow | 27 | 0 | 0 | No | No |
| 18334101 | Process for Preparing 2-[[5-(3-Chlorophenyl)-3-Hydroxypyridine-2-Carbonyl]Amino]Acetic Acid | June 2023 | December 2024 | Allow | 18 | 1 | 0 | No | No |
| 18205630 | SMALL MOLECULE STIMULATORS OF STEROID RECEPTOR COACTIVATOR-3 AND METHODS OF THEIR USE AS CARDIOPROTECTIVE AND/OR VASCULAR REGENERATIVE AGENTS | June 2023 | February 2025 | Allow | 21 | 2 | 0 | No | No |
| 18255247 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | May 2023 | March 2026 | Allow | 33 | 1 | 0 | No | No |
| 18254927 | NOVEL JAK-SPECIFIC INHIBITOR COMPOUND AND METHOD FOR PREPARING SAME | May 2023 | March 2026 | Abandon | 33 | 1 | 0 | No | No |
| 18324826 | ATF6 INHIBITORS AND USES THEREOF | May 2023 | January 2025 | Allow | 19 | 1 | 0 | No | No |
| 18253285 | PROCESS FOR PREPARING 7-CHLORO-6-FLUORO-1-(2-ISOPROPYL-4-METHYLPYRIDIN-3-YL)PYRIDO[2,3-D]PYRIMIDINE-2,4(1H,3H)-DIONE | May 2023 | February 2026 | Allow | 33 | 1 | 0 | No | No |
| 18314909 | PHARMACEUTICAL PREPARATION CONTAINING PYRIDYL AMINOACETIC ACID COMPOUND | May 2023 | January 2025 | Allow | 20 | 2 | 0 | No | No |
| 18315047 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | May 2023 | June 2025 | Abandon | 25 | 2 | 0 | No | No |
| 18035332 | DICYCLOPROPYLMETHYL DERIVATIVES AS IL-17 MODULATORS | May 2023 | February 2026 | Allow | 33 | 1 | 0 | No | No |
| 18309281 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | April 2023 | January 2025 | Allow | 21 | 3 | 0 | No | No |
| 18140129 | Modulators of BCL6 as Ligand Directed Degraders | April 2023 | April 2025 | Allow | 24 | 0 | 0 | Yes | No |
| 18306978 | INHIBITORS OF UBIQUITIN SPECIFIC PEPTIDASE 22 (USP22) AND USES THEREOF FOR TREATING DISEASES AND DISORDERS | April 2023 | January 2026 | Allow | 33 | 0 | 1 | Yes | No |
| 18130619 | SULPHONAMIDES AS METHIONINE METABOLIC PATHWAY INHIBITORS | April 2023 | May 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18190920 | PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | March 2023 | January 2025 | Allow | 22 | 1 | 0 | No | No |
| 18027602 | PYRIDO[4,3-b]INDOLE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | March 2023 | March 2026 | Abandon | 36 | 1 | 0 | No | No |
| 18043707 | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | March 2023 | March 2026 | Abandon | 36 | 0 | 1 | No | No |
| 18043385 | MODIFIED IMIDAZOPYRIDINES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | February 2023 | December 2025 | Allow | 33 | 1 | 0 | No | No |
| 18021930 | PYRROLOPYRIDINE DERIVATIVE AND USE THEREOF | February 2023 | November 2025 | Allow | 33 | 1 | 0 | No | No |
| 18040129 | SULFONYLAMIDINE SUBSTITUTED COMPOUNDS AND THEIR USE AS BETA-LACTAMASE INHIBITORS | January 2023 | July 2025 | Allow | 30 | 0 | 0 | No | No |
| 18004276 | Urea Co-Crystal of Apixaban, and Preparation Method Therefor | January 2023 | February 2026 | Abandon | 37 | 1 | 0 | No | No |
| 18013803 | COMPOSITIONS AND METHODS FOR MODULATING HAIR GROWTH | December 2022 | October 2025 | Allow | 34 | 1 | 0 | Yes | No |
| 18068005 | SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | December 2022 | March 2025 | Allow | 27 | 2 | 0 | Yes | No |
| 18010920 | IMMUNOSUPPRESSANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | December 2022 | September 2025 | Allow | 33 | 0 | 1 | Yes | No |
| 18008083 | DEUTERATED IRAK DEGRADERS AND USES THEREOF | December 2022 | January 2026 | Allow | 37 | 2 | 0 | No | No |
| 18073768 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | December 2022 | January 2025 | Allow | 25 | 1 | 1 | No | No |
| 17927406 | SUBSTITUTED INDOLES WITH INHIBITORY ACTIVITY | November 2022 | December 2025 | Allow | 36 | 1 | 1 | Yes | No |
| 17981310 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | November 2022 | October 2025 | Abandon | 36 | 1 | 1 | No | No |
| 17974342 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | October 2022 | August 2024 | Allow | 21 | 1 | 1 | No | No |
| 17973119 | NOVEL ERGOLINES AND METHODS OF TREATING MOOD DISORDERS | October 2022 | December 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17920630 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | October 2022 | October 2025 | Allow | 35 | 1 | 0 | Yes | No |
| 17916845 | BCL-2 INHIBITOR | October 2022 | December 2024 | Allow | 26 | 1 | 0 | No | No |
| 17910486 | CRYSTAL OF IMIDAZOPYRIDINONE COMPOUND OR SALT THEREOF | September 2022 | December 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17904809 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | August 2022 | September 2025 | Allow | 37 | 1 | 0 | Yes | No |
| 17793498 | PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS | July 2022 | December 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17790091 | SMALL MOLECULE INHIBITORS OF ULK1 | June 2022 | July 2025 | Allow | 36 | 1 | 0 | No | No |
| 17757824 | PYRIDO[2,3-D]PYRIMIDINE HIV-1 REVERSE TRANSCRIPTASE INHIBITOR WB3, PREPARATION METHOD AND APPLICATION THEREOF | June 2022 | October 2025 | Abandon | 40 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner RAHMANI, NILOOFAR.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 61.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner RAHMANI, NILOOFAR works in Art Unit 1691 and has examined 572 patent applications in our dataset. With an allowance rate of 99.3%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 25 months.
Examiner RAHMANI, NILOOFAR's allowance rate of 99.3% places them in the 93% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by RAHMANI, NILOOFAR receive 0.98 office actions before reaching final disposition. This places the examiner in the 8% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by RAHMANI, NILOOFAR is 25 months. This places the examiner in the 78% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a -0.2% benefit to allowance rate for applications examined by RAHMANI, NILOOFAR. This interview benefit is in the 12% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 47.0% of applications are subsequently allowed. This success rate is in the 96% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 84.5% of cases where such amendments are filed. This entry rate is in the 97% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 83.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 47.9% are granted (fully or in part). This grant rate is in the 43% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 25.5% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.1% of allowed cases (in the 61% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.